[Home] [About us] [Pipeline ] [Alzheimer' Drugs] [Covid Drugs] [Clinical] [Collaboration] [News] [Contact]
Pioneer in Preventing and Treating Incurable Diseases
NeuroActiva™ Inc.
NeuroActiva™ Inc. is a clinical stage bio-pharmaceutical company committed to the discovery and development of new drugs to prevent and treat Alzheimer's disease and Covid-19.
Read MoreABOUT US
NeuroActiva™ is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of new drugs to treat and prevent Alzheimer’s disease and Covid-19
TECHNOLOGY
We have developed patented neuroprotection and neurogenesis methods that can prevent and treat Alzheimer's disease, as well as combination therapy with anti-viral drugs to treat Covid-19
PIPELINES
Our therapeutic product pipelines include NA-831 (Traneurocin) and Vineurocin™ (NA-704™) for the prophylaxis and treatment of Alzheimer's disease and a combination drug therapy for Covid-19
ALZHEIMER DRUGS
NA-831™)(Traneurocin™) and NA-740™ (Vineurocin™) are novel neuroprotective and neurogenesis drug for treatment of Alzheimer's disease which will be in Phase 3 in 2020-2021.
.COVID DRUGS
We have developed drug combination therapy known as Biomedivr™, Neuromedivir™, Dexaneurosone™ Neurosivir™ for the prophylaxis and treatment of Covid-19
MICROS™ Infuser
The MICROS™ is a FDA approved intravenous drug delivery system for injectable drugs, including NA-704 for treatment of neurological diseases in homecare settings.
Prophylaxis and treatment for Alzheimer's disease and Covid-19:
-
Covid-19 Neuro-invasion
SARS-CoV-2 can directly invade the CNS. NeuroActiva has developed neuroprotective interventions during the severe acute respiratory syndrome, and provide appropriate rehabilitation measures afterwards.
-
NA-831 (Traneurocin)
(NA-831™)(Traneurocin™) is a novel neuroprotective and neurogenesis drug for treatment of Alzheimer's disease which will be in Phase 3 in 2020-2021
-
NA-831™ Drug Therapy
We have developed drug combination therapy known as Biomedivr™, Neuromedivir™, Dexaneurosone™ Neurosivir™ for the prophylaxis and treatment of Covid-19
-
MICROS™ Infusion System
The MICROS is a FDA approved controlled release infusion system for intravenous administration of injectable drugs, including NA-704 for treatment of neurological diseases.
